Whitney Wharton1,2, Liping Zhao3, Kyle Steenland4, Felicia C Goldstein1, Julie A Schneider5,6, Lisa L Barnes6, Marla Gearing1, Sevil Yasar7. 1. Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA. 2. Emory University, School of Nursing, Atlanta, GA, USA. 3. Emory University Department of Biostatistics and Bioinformatics, School of Public Health, Atlanta, GA, USA. 4. Rollins School of Public Health, Biostatistics and Bioinformatics, Atlanta, GA, USA. 5. Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA. 6. Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA. 7. Johns Hopkins University School of Medicine, Department of Medicine, Baltimore, MD, USA.
Abstract
BACKGROUND: Individuals taking renin angiotensin system (RAS) acting antihypertensives exhibit slower cognitive decline and are less likely to progress from mild cognitive impairment (MCI) to Alzheimer's disease (AD), but the mechanism remains unclear. OBJECTIVE: We tested the hypothesis that individuals taking RAS acting antihypertensives exhibit less AD-related neuropathology and slower disease progression than individuals taking non-RAS acting antihypertensives. METHOD: Participants included 83 individuals with MCI who were taking an antihypertensive at baseline, had at least two follow-up visits, and had postmortem neuropathological data. Participants were old (M = 83.1 years), 32% male, well educated (M = 15.7 years), and 9.2% Black. RESULTS: RAS medication users (N = 38) were less likely to progress to AD than non-RAS users (N = 45). RAS users exhibited fewer neurofibrillary tangles than non-RAS users in the hippocampal CA1 region (p < 0.01), entorhinal cortex (p = 0.03), and the angular gyrus, inferior temporal, mid-frontal cortex, and superior frontal (p = 0.01). CONCLUSION: Prevention or clearance of neurofibrillary tangles represents a mechanism by which RAS medications may slow disease progression.
BACKGROUND: Individuals taking renin angiotensin system (RAS) acting antihypertensives exhibit slower cognitive decline and are less likely to progress from mild cognitive impairment (MCI) to Alzheimer's disease (AD), but the mechanism remains unclear. OBJECTIVE: We tested the hypothesis that individuals taking RAS acting antihypertensives exhibit less AD-related neuropathology and slower disease progression than individuals taking non-RAS acting antihypertensives. METHOD: Participants included 83 individuals with MCI who were taking an antihypertensive at baseline, had at least two follow-up visits, and had postmortem neuropathological data. Participants were old (M = 83.1 years), 32% male, well educated (M = 15.7 years), and 9.2% Black. RESULTS: RAS medication users (N = 38) were less likely to progress to AD than non-RAS users (N = 45). RAS users exhibited fewer neurofibrillary tangles than non-RAS users in the hippocampal CA1 region (p < 0.01), entorhinal cortex (p = 0.03), and the angular gyrus, inferior temporal, mid-frontal cortex, and superior frontal (p = 0.01). CONCLUSION: Prevention or clearance of neurofibrillary tangles represents a mechanism by which RAS medications may slow disease progression.
Authors: Reisa A Sperling; Paul S Aisen; Laurel A Beckett; David A Bennett; Suzanne Craft; Anne M Fagan; Takeshi Iwatsubo; Clifford R Jack; Jeffrey Kaye; Thomas J Montine; Denise C Park; Eric M Reiman; Christopher C Rowe; Eric Siemers; Yaakov Stern; Kristine Yaffe; Maria C Carrillo; Bill Thies; Marcelle Morrison-Bogorad; Molly V Wagster; Creighton H Phelps Journal: Alzheimers Dement Date: 2011-04-21 Impact factor: 21.566
Authors: Marilyn S Albert; Steven T DeKosky; Dennis Dickson; Bruno Dubois; Howard H Feldman; Nick C Fox; Anthony Gamst; David M Holtzman; William J Jagust; Ronald C Petersen; Peter J Snyder; Maria C Carrillo; Bill Thies; Creighton H Phelps Journal: Alzheimers Dement Date: 2011-04-21 Impact factor: 21.566
Authors: E Savaskan; C Hock; G Olivieri; S Bruttel; C Rosenberg; C Hulette; F Müller-Spahn Journal: Neurobiol Aging Date: 2001 Jul-Aug Impact factor: 4.673
Authors: Juan C Arias; Mark Edwards; Francesca Vitali; Thomas G Beach; Geidy E Serrano; Craig C Weinkauf Journal: J Vasc Surg Date: 2021-08-31 Impact factor: 4.268
Authors: Charles E Evans; James S Miners; Giulia Piva; Christine L Willis; David M Heard; Emma J Kidd; Mark A Good; Patrick G Kehoe Journal: Acta Neuropathol Date: 2020-01-25 Impact factor: 15.887